Aaron S. Kemp
  • Irvine, CA
  • United States
Share on Facebook
Share Twitter
  • NeuroNetwork Blog Posts
  • Events
  • Groups
 

Aaron S. Kemp's Page

Latest Activity

Aaron S. Kemp is now a member of The NeuroNetwork
Oct 18, 2010

Profile Information

Main areas of research:
Advanced methodologies for administering neurocognitive assessments in CNS clinical trials. Developmental origins and neural processes subserving neurocognitive dysfunctions associated with CNS disorders.
Interests/keywords:
neurocognitive assessment, clinical trials, CNS disorders
Current title/position:
Director of Scientific Affairs
Current affiliation/employer:
NeuroComp Systems, Inc.
Collaborators:
James P. O'Halloran, PhD
Melvin Lyon, PhD
Curt A. Sandman, PhD
Magnus Magnusson, PhD
Steven G. Potkin, MD
William E. Bunney, Jr., MD
Julie V. Patterson, PhD
Yi Jin, MD
Adrian Preda, MD
Dana Nguyen, PhD
Personal or laboratory homepage:
http://www.linkedin.com/in/akemp
Publications:
Book Chapter:

Sandman CA & Kemp AS (2007). Neuroscience of Developmental Disabilities. In Odom SL, Horner RH, Snell M, Blacher J (Eds.), Handbook of Developmental Disabilities. Guilford Press.

Journal Articles:

Lyon M & Kemp AS (2004). Increased Temporal Patterns in Choice Responding and Altered Cognitive Processes in Schizophrenia and Mania. Psychopharmacology,172(2):211-219.

Jin Y, Potkin SG, Kemp AS, Huerta S, Alva G, Thai T, Carreon D, Bunney WE (2006). Therapeutic Effects of Individualized Alpha Frequency Transcranial Magnetic Stimulation (αTMS) on the Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 32(3):556-561.

O'Halloran JP, Kemp AS, Gooch K, Harvey P, Palmer B, Reist C, Schneider L (2008). Psychometric Comparison of Computerized and Standard Administration of the Neurocognitive Assessment Instruments Selected by the CATIE and MATRICS Consortia among Patients with Schizophrenia. Schizophrenia Research, 106(1):33-41.

Kemp AS, Schooler N, Kalali A, Alphs L, Anand R, Awad G, Davidson M, Dube S, Ereshefsky L, Gharabawi G, Leon A, Lepine JP, Potkin S, Vermeulen A (2008). What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophrenia Bulletin, 36(3):504-509.

Kemp AS (2008). “Plenary Topic: Advancing Drug Development in Schizophrenia” & “Strategies to Accelerate Drug Development for Schizophrenia”. In: Abubaker, et al., DeLisi L (Ed.). Summary of the 1st Schizophrenia International Research Society Conference Oral Sessions, Venice, Italy, June 21-25, 2008: The Rapporteur Reports. Schizophrenia Research, 105:289-383.

Kemp AS, Grossberg GT, Romano SJ, Arnold D, Ryan JM, Bullock R, Streiner DL (2009). Trial designs likely to meet valid long-term Alzheimer’s disease progression effects: Learning from the past, preparing for the future. International Journal of Alzheimer’s Disease (in press).

Jin Y, Kemp AS, Huang Y, Thai T, Liu Z, Xu W, He H, Brokaw A, Potkin SG (under review). Efficacy of αTMS in Schizophrenia: A Multi-National, Randomized, Double-Blind, Sham-Controlled Trial for EEG-Guided, Alpha-Frequency Transcranial Magnetic Stimulation. Brain Stimulation.

Kemp AS, Mohs R, Salmon D, Tariot P, Ismail MS, Sano M, Schneider L, O’Halloran JP (under review). Psychometric Comparison of Computerized and Standard Administration of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog). Current Alzheimer’s Research.

Selected Poster Presentations:

Kemp AS, Gooch KN, Goldberg JL, Bun S, Gripeos D, Reist C, Palmer BW, Bondi M, O’Halloran JP (2009). Preliminary Evaluation of the Concurrent Validity of Remote-Televideo and Face-To-Face Administration of a Computerized Neurocognitive Assessment Battery. 5th Annual Scientific Meeting of the ISCTM, Arlington, VA, March 3-5; and the 49th Annual NCDEU Meeting, Hollywood, FL; June 29 - July 2.

Kemp AS, Mohs R, Salmon D, Tariot P, Ismail MS, Sano M, Schneider L, O’Halloran JP (2008). Psychometric Comparison of Computerized and Standard Administration of the Alzheimer’s Disease Assessment Scale (ADAS) among Patients with Mild to Moderate Alzheimer’s Disease. 2008 Autumn Conference of the ISCTM; Toronto, ON; October 5-7. Received the 2008 Distinguished Poster Award.

Kemp AS, Turner J, Lee HJ, Trondsen L, Gooch K, Mirski D, Potkin SG, fBIRN (2005). The Neurocognitive Correlates of BOLD Activation in the Dorsolateral Prefrontal Cortex of Patients with Schizophrenia: An fMRI Investigation. Schizophrenia Bulletin, 31 (2): 424. ICOSR, Savannah, GA, April 2-6.

Kemp AS, Fleming K, Cohen E, Jin Y, Highum D, Alva G, Bunney WE, Potkin SG (2001). A Neurocognitive Evaluation of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex of Patients with Prominent Negative Symptom Schizophrenia. Schizophrenia Research, 49 (1-2), 111. International Congress on Schizophrenia Research (ICOSR), Whistler, B.C., May 2-6.

Comment Wall

You need to be a member of The NeuroNetwork to add comments!

Join The NeuroNetwork

  • No comments yet!
 
 
 

© 2014   Created by Springer.

Badges  |  Report an Issue  |  Terms of Service